Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Alterations in miRNA Levels in the Dentate Gyrus in Epileptic Rats

Alterations in miRNA Levels in the Dentate Gyrus in Epileptic Rats

  • Anna Maria Bot, 
  • Konrad Józef Dębski, 
  • Katarzyna Lukasiuk
PLOS
x

Abstract

The aim of this study was to characterize changes in miRNA expression in the epileptic dentate gyrus. Status epilepticus evoked by amygdala stimulation was used to induce epilepsy in rats. The dentate gyri were isolated at 7 d, 14 d, 30 d and 90 d after stimulation (n=5). Sham-operated time-matched controls were prepared for each time point (n=5). The miRNA expression was evaluated using Exiqon microarrays. Additionally, mRNA from the same animals was profiled using Affymetrix microarrays. We detected miRNA expression signatures that differentiate between control and epileptic animals. Significant changes in miRNA expression between stimulated and sham operated animals were observed at 7 and 30 d following stimulation. Moreover, we found that there are ensembles of miRNAs that change expression levels over time. Analysis of the mRNA expression from the same animals revealed that the expression of several mRNAs that are potential targets for miRNA with altered expression level is regulated in the expected direction. The functional characterization of miRNAs and their potential mRNA targets indicate that miRNA can participate in several molecular events that occur in epileptic tissue, including immune response and neuronal plasticity. This is the first report on changes in the expression of miRNA and the potential functional impact of these changes in the dentate gyrus of epileptic animals. Complex changes in the expression of miRNAs suggest an important role for miRNA in the molecular mechanisms of epilepsy.

Introduction

Epilepsy is one of the most prevalent serious neurological disorders, affecting approximately 1% of the world’s population [1]. It is estimated that approximately 50 million people worldwide and 6 million in Europe alone have active epilepsy. Approximately 30% of these patients are drug refractory [2]. The health and indirect social costs associated with epilepsy are a considerable burden for society.

In many cases, epilepsy develops as the result of a brain damaging insult that initiates cascades of events, called epileptogenesis (latency period), after which recurrent spontaneous seizures occur [3]. Epileptogenic insult causes a number of changes that lead to the remodeling of neuronal circuits and subsequent seizures, however it is still not clear which of them are causative [4,5]. One method to elucidate the processes underlying epilepsy that has been successfully used is the analysis of global changes in the transcriptome to distinguish metabolic pathways affected by epileptic processes [6-10]. Very recently, general mechanisms of the regulation of gene expression, in addition to the gene expression patterns, have become of interest. In particular the role of epigenetic mechanisms including DNA methylation and miRNA, have been investigated [11,12].

miRNAs are small (20-24 bp), non-coding RNAs that regulate the expression of target genes by binding to the 3’-untranslated regions (UTR) of target mRNAs. It is estimated that miRNAs regulate as much as 60% of mRNAs and that one miRNA can target a few to several hundred genes [13], which makes miRNAs very powerful players in the regulation and fine-tuning of gene expression. Alterations in miRNAs levels can have pronounced effects.

Brain has an exceptionally high expression of miRNAs. Approximately 60% of all miRNA species are present in the brain [14]. This suggests a particularly significant role for miRNAs in brain physiology, as well as the possibility of serious consequences in cases of miRNA dysfunction. In fact, changes in the expression levels of individual miRNAs have been observed in physiological conditions, including learning and memory formation, neuronal development and plasticity, as well as pathological conditions, such as psychiatric diseases, neurodegeneration, ischemia, Alzheimer’s disease, and epilepsy [12,15-19].

Currently, data on the role of miRNAs in epilepsy are limited. Dysfunction of miRNA processing and decrease in miRNA levels as well as alterations in expression of individual miRNAs were observed in temporal lobe epilepsy patients with hippocampal sclerosis [20-22]. Few studies report changes in miRNA expression in the hippocampus of epileptic rats in pilocarpine or lithium-pilocarpine models of epilepsy [23-25].

In the present work we decided to investigate changes in the expression levels of miRNAs in the dentate gyrus, a structure that has been studied for a long time in the context of epilepsy and epilepsy development. For instance, in the epileptic dentate gyrus, the occurrence of abnormal neuronal plasticity, abnormal neurogenesis, alterations in GABA-mediated inhibition and neurodegeneration limited to certain populations of neurons have been observed [26-28]. Here we describe miRNA expression patterns at different times following epileptogenic stimulus in the animal model of temporal lobe epilepsy. Additionally we propose potential mRNA targets by evaluating the mRNA expression levels in the same tissue samples. This is the first report on changes in the expression of miRNA and the potential functional impact of these changes in the dentate gyrus of epileptic animals.

Materials and Methods

Animal surgery and status epilepticus induction

Adult male Sprague-Dawley rats (Medical Research Centre, Warsaw, Poland) weighing 290–320 g were used in this study. Animals were housed in a controlled environment (22°C ± 1°C, lights on 07:00–19:00) with free access to food and water. Starting from the day of surgery, each animal was housed in a separate cage. All animal procedures were approved by the Ethical Committee on Animal Research of the Nencki Institute and conducted in accordance with the guidelines established by The European Council Directives 2010/63/EU.

The amygdala stimulation model of temporal lobe epilepsy was used in this study [29].

Status epilepticus (SE) was triggered by electrical stimulation of the amygdala as previously described by Guzik-Kornacka et al. [30] with some modifications. Briefly, surgery was performed under isoflurane anesthesia (2-2.5% in 100% O2) preceded by the injection of butorphanol (Butomidor, Richter Pharma AG, Wells, Austria; 0.5 mg/kg i.p.). A stimulating and recording bipolar wire electrode (Plastic One Inc., Roanoke, VA, # E363-3-2WT-SPC) was implanted into the left lateral nucleus of the amygdala 3.6 mm posterior and 5.0 mm lateral to bregma, 6.5 mm ventral to the surface of the brain [31]. A stainless steel screw electrode (Plastic One Inc., Roanoke, VA, #E363/20) was implanted contralaterally into the skull over the right frontal cortex (3.0 mm anterior and 2.0 mm lateral to bregma) as a surface EEG recording electrode. Two stainless steel screw electrodes were placed bilaterally over the cerebellum (10.0 mm posterior and 2.0 mm lateral to bregma) as ground and reference electrodes. The socket contacts of all electrodes were placed in a multi-channel electrode pedestal (Plastic One Inc., Roanoke, VA, #MS363) which was attached to the skull with dental acrylate (Duracryl Plus). After 2 weeks of recovery, animals were electrically stimulated via the intra-amygdala electrode to evoke status epilepticus. Stimulation consisted of a 100-ms train of 1-ms biphasic square-wave pulses (400 µA peak to peak) delivered at 60 Hz every 0.5 s for 30 min. If the animal did not enter status epilepticus, stimulation was continued for an additional 10 min. The SE was stopped 1.5-2 h after stimulation via an intraperitoneal injection of diazepam (20 mg/kg). If the first dose of diazepam did not suppress SE, the animal received subsequent doses of diazepam at 5 mg/kg. Time-matched control animals had electrodes implanted but did not receive electrical stimulation.

Rats sacrificed at 7 d, 14 d, and 30 d after SE were monitored with video-EEG (Comet EEG, Grass Technologies, West Warwick, RI) continuously from the moment of stimulation until the end of the experiment. Rats sacrificed 90 d after SE were monitored for 5 d after stimulation and then for 2 weeks before the end of experiment to determine the frequency of spontaneous seizures. Spontaneous seizures were identified from EEG recordings by browsing the EEG manually on the computer screen. An electrographic seizure was defined as a high frequency (>8 Hz), high amplitude (>2x baseline) discharge lasting for at least 5 s. Latency to the first spontaneous seizure, number and frequency of seizures, and number of epileptic animals in each group were evaluated.

For tissue collection, the rats were anaesthetized with CO2 and decapitated with a guillotine. The brains were removed from the skull and the hippocampi were isolated on an ice cold plate and placed in RNAlater solution (Ambion, AM7024) then stored at -20°C until use.

miRNA isolation and profiling

The left dentate gyrus region was dissected under a dissection microscope. The isolation of total RNA including miRNA, was performed using the miRNeasy Mini kit (QIAGEN, # 217004) according to the manufacturer’s instructions. The sample concentration and contamination with protein or organic compounds were determined using a NanoDrop 2000 spectrophotometer (Thermo, Fisher Scientific). All samples had Abs 260/280 >2.0 and 260/230 >1.4. The quality of the total RNA was further verified using the an Agilent 2100 Bioanalyzer.

The miRNA array profiling experiment was performed at Exiqon Services, Denmark using the miRCURY LNATM microRNA Array 7th targeting all microRNAs for human, mouse or rat registered in the miRBASE version 19.0 at the Sanger Institute. The data are available at Gene Expression Omnibus under the accession number GSE49850 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49851).

Transcriptome profiling

GeneChip® Rat Gene 1.1 ST arrays (Affymetrix, Santa Clara, CA, # 901627) were used for mRNA profiling. The same mRNA samples were used for miRNA and mRNA profiling. One hundred nanograms of total mRNA was used for cDNA synthesis using an Ambion WT Expression Kit (Life Technologies, # 4411974). Hybridization, washing and scanning were conducted according to Affymetrix guidelines for the GeneAtlasTM instrument. The data are available at Gene Expression Omnibus under the accession number GSE49849 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49851).

Data analysis

The preliminary analysis of miRNA microarrays identifying upregulated and downregulated miRNAs was performed by the Exiqon Company. All calculations were performed with the software R/Bioconductor [32,33] primarily with the limma package [34]. For the expression analysis, the calculated p-values were based on moderated t-statistics. Furthermore, the Benjamini and Hochberg multiple testing adjustment method was applied to the p-values (FDR – False Discovery Rate).

The correlation, cluster and principal component analyses were performed in the R environment (version 15.1) [33].

Principal component analysis (PCA) was performed on all 292 microarray probes with an intensity greater than the background value using the function prcomp (package stats). A PCA plot (splom) was generated with the lattice package [35].

For the heatmap clustering of miRNAs with significantly different expression (FDR < 0.05) between all epileptic and sham-operated control animals, miRNAs were ordered with the clustering complete-linkage method together with the Pearson correlation distance measure. The heatmap diagram was generated with the gplots package [36]

Pearson correlation test was used to analyze the correlations between miRNAs with significantly different expression (FDR < 0.01) between stimulated and sham-operated control animals. A correlation plot was generated with the corrplot package [37].

The fuzzy c-means algorithm implemented in the Mfuzz package [38] was used to perform clusterization on all 292 probes that had expressions higher than the background. The functional analysis of miRNA belonging to individual clusters was performed using the Ingenuity Pathways analysis software (Ingenuity Systems, Redwood City, CA).

Analysis of the Affymetrix Rat Gene 1.1 ST arrays was performed using R/Bioconductor [33]. The microarrays were normalized with the Robust Multi-array Average (RMA) algorithm (oligo package version 1.22.0) [39]. The intensity of the genomic probes below the median intensity of antigenomic probes (considered as a background value) were corrected to this median value. Probes with intensity equal to or lower than the background in more than five samples were removed from analysis. Only probes that corresponded to a single gene were selected for further analysis. A one-way ANOVA was used to establish genes that were differentially expressed between groups.

The miRNA targets were selected using the Ingenuity Pathways analysis software (Ingenuity Systems, Redwood City, CA) containing a manually curated collection of miRNA-target interactions. Only mRNAs with significantly changing expression levels (p<0.05) in comparison to the time-matched controls were included. Of those, only mRNAs changing expression level in the opposite direction to that of the miRNAs were selected for presentation.

DAVID (version 6.7) [40,41] was used for the functional annotation of potential gene targets. The Biological Process Gene Ontology (GO) was analyzed using the Functional Annotation Clustering tool with the default Rattus norvegicus background. The resulting Annotation Clusters were named in a way that best described their GO terms.

Results

We evaluated the expression of miRNA in the dentate gyrus of epileptic animals sacrificed at 7, 14, 30 and 90 days following amygdala stimulation-induced SE and time-matched sham controls. All stimulated animals included in the study developed spontaneous seizures and were therefore diagnosed with epilepsy. Rats from the 7 d, 14 d and 30 d groups were monitored with a video-EEG system continuously from the moment of stimulation until the end of the experiment, while animals from 90 d group were only monitored for 2 wks preceding tissue collection. The median number of seizures during the monitoring period was as follows: 1 (range 0-4) in the 7 d group, 11 (range 1-17) in the 14 d group, 11 (range 5-24) in the 30 d group, and 8 (range 3-17) in the 90 d group. The number of seizures during the last one week of monitoring was as follows: 2 (range 1-12) in 14 d group, 6 (range 2-14) in the 30 d group, and 4 (range 0-14) in the 90 d group.

To detect similarities and differences between samples, PCA analysis was performed. The results of the PCA performed on all miRNA probes with an intensity greater than the background indicated, that the miRNA expression profiles of the sham-operated controls and stimulated animals were different (Figure 1A). The profiles of the epileptic animals were grouped together and are separate from the controls.

thumbnail
Figure 1. miRNA expression profiles in the dentate gyrus of epileptic and sham-operated control animals at different times after SE.

(A) Principle Component Analysis (PCA) of microarray data derived from epileptic (red) and sham-operated control animals (blue) at 7 d (square), 14 d (circle), 30 d (triangle), and 90 d (cross) after status epilepticus. Each mark represents an individual animal. Note that epileptic animals are separate from the controls. (B) A heatmap of the 66 miRNAs with altered expression levels in epileptic animals (Table 1). Each column represents an individual animal and each row represents an individual miRNA. Colors on the heatmap represent the Z-score: higher – red, lower – green. Red color in the bar over the heatmap panel represents epileptic animals, and blue represents sham-operated control animals.

http://dx.doi.org/10.1371/journal.pone.0076051.g001

To detect prolonged changes in miRNA expression levels regardless of the time point, we analyzed the differences in the expression levels of individual miRNAs between all sham-operated controls and all stimulated animals. We detected significant changes in the expression of 66 miRNAs. Table 1 lists all miRNAs for which the expression levels differed between the sham-operated and epileptic animals at an adjusted p-value of 0.05. Nine miRNAs were upregulated, while 57 miRNAs were downregulated. The largest decreases in expression were observed in miR-187-3p, miR-551b-3p and miR-7a-5p at 0.61, 0.67 and 0.71 fold of the control levels respectively. The largest increases in expression occurred in miR-212-3p, miR-132-3p and miR-21-5p at 1.54, 1.52 and 1.41 fold of the control levels respectively (Table 1).

EXIQON probemicroRNAlogFCFDR
42627miR-212-3p0.620.0004
10937miR-132-3p0.60.003
147506miR-21-5p0.530.0028
145634miR-132-5p0.50.0062
148304miR-212-5p0.40.0062
10952miR-146a-5p0.350.0264
42744miR-23a-3p0.340.0243
148300miR-370-5p0.320.012
148099miR-344b-2-3p0.140.0394
11231miR-345-5p-0.150.0363
13150miR-322-5p-0.160.0062
42898miR-124-5p-0.160.0252
31388miR-291a-5p-0.160.0486
148614miR-7a-2-3p-0.160.0486
148278miR-138-2-3p-0.180.0429
42606miR-330-3p-0.20.0264
33902miR-128-3p-0.210.0429
14316miR-664-3p-0.210.0429
145825miR-383-5p-0.220.0221
42792miR-29b-2-5p-0.220.0243
11277miR-7a-1-3p-0.220.0243
46917miR-205-0.230.0243
148175miR-1843-3p-0.230.0264
42847miR-497-5p-0.230.0269
11041miR-29c-3p-0.230.0343
4390miR-7b-0.230.0377
168937miR-138-1-3p-0.230.0432
42669miR-505-3p-0.230.0432
19595miR-30a-3p-0.240.0252
148477miR-1843-5p-0.250.0178
148017miR-743a-5p-0.250.0377
18739miR-186-5p-0.250.0396
10919miR-103-3p-0.250.047
42477miR-324-5p-0.250.0482
145708miR-324-3p-0.270.0321
14328miR-124-3p-0.270.0363
145843miR-330-5p-0.280.0377
42800miR-582-5p-0.290.0199
10923miR-107-3p-0.290.0377
10306miR-146b-5p-0.290.0429
19585miR-148b-3p-0.30.0243
11065miR-335-0.30.0264
13143miR-301a-3p-0.30.0383
145638miR-29a-5p-0.30.0419
146112miR-30b-5p-0.30.0419
145742miR-935-0.30.0429
10138miR-130a-3p-0.310.0243
27536miR-190a-5p-0.320.0178
11052miR-31a-5p-0.330.002
148519miR-3580-3p-0.330.0264
14300miR-29c-5p-0.340.01
148131miR-9b-5p-0.350.0264
147198miR-26a-5p-0.390.0132
11018miR-218a-5p-0.40.008
145749miR-137-3p-0.40.0178
29190miR-708-5p-0.420.008
31026miR-101a-3p-0.420.047
146086miR-30a-5p-0.430.012
145859miR-33-5p-0.430.0176
19596miR-30d-5p-0.440.0178
145677miR-139-5p-0.470.0188
148098miR-374-5p-0.480.002
28191miR-30e-5p-0.480.0121
29490miR-7a-5p-0.490.0105
148644miR-551b-3p-0.570.0066
145637miR-187-3p-0.710.0001

Table 1. List of miRNAs differentially expressed between all stimulated and all control animals (FDR<0.05).

miRNAs are ordered according to decreasing logFC
CSV
Download CSV

Heatmap of 66 miRNAs with altered expression levels in stimulated animals revealed different expression patterns between the control and epileptic animals (Figure 1B). Two main clusters generated by this analysis act as the first division branches, segregating the sham-operated control animals from the stimulated ones. The exceptions are two animals sacrificed at 90 d after stimulation, which were more similar to the sham-operated control animals. Within the cluster of stimulated animals, fractions of rats belonging to the 7 d group as well as those belonging to the 30 d group formed distinguishable clusters.

When the differences in miRNA expression between the stimulated animals and time-matched controls were evaluated, statistically significant differences were found for the 7 d and 30 d time points (Tables 2 and 3). At 7 d after stimulation, 3 miRNAs were upregulated and 20 miRNAs were downregulated (Table 2). The most upregulated microRNAs were miR-132-3p, miR-212-3p and miR-21-5p, which were increased by 1.75, 1.83 and 1.89-fold respectively. The largest decrease in expression was observed in miR-7a-5p, miR-551b-3p and miR-187-3p at 0.53, 0.56 and 0.56-fold of the control, respectively. At the 30 d time point, changes in the expression of 20 miRNAs were observed. In comparison to the 7 d time point, a greater number of miRNAs were upregulated [11] than downregulated [9]. The most upregulated miRNAs were miR-146a-5p, miR-132-5p, miR-21-5p at 1.63, 1.61, and 1.56-fold of the control, respectively, while the most downregulated miRNAs were miR-29b-3p, miR-352, miR-30e-5p at 0.60, 0.70, and 0.72-fold of the control, respectively.

EXIQON probemiRNAlogFCFDR
147506miR-21-5p*0.9190.011
42627miR-212-3p0.8750.005
10937miR-132-3p0.8030.011
148300miR-370-5p*0.590.035
148614miR-7a-2-3p-0.4520.037
145633let-7d-3p-0.4880.046
169394miR-1843-5p-0.5190.038
148477miR-1843-5p-0.5220.037
14328miR-124-3p-0.5670.037
13143miR-301a-3p-0.5690.049
42477miR-324-5p-0.6010.037
145638miR-29a-5p-0.6410.037
29190miR-708-5p-0.660.032
145742miR-935-0.6750.037
145897miR-92b-3p-0.7240.037
148098miR-374-5p*-0.7270.017
145640miR-328a-3p-0.7560.037
145677miR-139-5p-0.770.024
19596miR-30d-5p-0.7780.011
145859miR-33-5p*-0.8010.032
145637miR-187-3p*-0.8420.032
148644miR-551b-3p-0.8470.027
29490miR-7a-5p-0.9280.007

Table 2. miRNAs changing expression levels at 7 d after status epilepticus (FDR<0.05).

*common with 30-d time point miRNAs are ordered according to decreasing logFC
CSV
Download CSV
EXIQON probemiRNAlogFCFDR
10952miR-146a-5p0.7020.032
145634miR-132-5p0.6870.01
147506miR-21-5p*0.640.005
148304miR-212-5p0.6150.006
42744miR-23a-3p0.5170.02
168586miR-34a-5p0.5020.009
148300miR-370-5p*0.3950.018
29153miR-34b-5p0.3710.02
42950miR-24-2-5p0.3190.02
168831miR-433-3p0.3010.035
11074miR-34c-5p0.2760.032
14300miR-29c-5p-0.2840.02
146086miR-30a-5p-0.30.02
148098miR-374-5p*-0.3010.032
145859miR-33-5p*-0.3830.006
11018miR-218a-5p-0.40.005
145637miR-187-3p*-0.4630.033
28191miR-30e-5p-0.4810.007
11273miR-352-0.5120.02
11040miR-29b-3p-0.7360.02

Table 3. miRNAs that changed expression levels at 30 d after status epilepticus (FDR<0.05).

*common with 7-d time point miRNAs are ordered according to decreasing logFC
CSV
Download CSV

We did not detect statistically significant differences (FDR<0.05) in miRNA expression between the control and stimulated animals at 14 d and 90 d. However, a number of the mean expression levels were similar to the expression levels at 7 d or 30 d after stimulation, but larger individual variability within the groups was observed (Figure 2). However, when the cut-off criteria for the selection of differentially expressed miRNA were relaxed, we could observe some changes at 14 d and 90 d after stimulation. At 14 d after stimulation, there were 4 miRNAs with different expression levels between the time-matched sham-operated and stimulated rats at unadjusted p<0.01 and 26 miRNAs at unadjusted p<0.05. At the 90 d time point, there were 2 miRNAs with different expression levels at unadjusted p<0.01 and 16 miRNAs with different expression levels at unadjusted p<0.05. We suppose that this lack of significance is due to individual differences between animals within the group (see also Figure 2). For this manuscript, we limited our analysis to the more restrictive cut-off.

thumbnail
Figure 2. Expression levels of selected miRNAs in individual sham-operated and stimulated animals.

The bottom and the top of the box indicate the first and the third quartile, the band within the box indicates the median and the ends of the whiskers represent the lowest and the highest datum still within 1.5 IQR (interquartile range) of the lower and upper quartile, respectively. Each dot represents one animal. Blue are sham operated animals, and red are stimulated animals.

http://dx.doi.org/10.1371/journal.pone.0076051.g002

The clusterization of all 292 miRNAs that had intensities greater than the background revealed several patterns of alteration in miRNA expression over time in SE rats (Figure 3A). For example there were miRNAs regulated in opposite directions at the 7 d and 14 d time points (Figure 3A, cluster 3 and 7). Other miRNAs were upregulated only up to 14-d after SE (Figure 3A, cluster 4). We used the Ingenuity Pathway software to approach the question of the functional significance of these changes in miRNA expression (Figure 3B, C). miRNA belonging to individual clusters may be involved in several diseases. In particular, functions related to cancer are frequently represented. In several clusters, miRNA involved in neurological diseases and normal brain functions are present. miRNAs belonging to each cluster and functional classes are listed in Table S2.

thumbnail
Figure 3. Clustering analysis of the miRNA with altered expression levels in epileptic animals.

(A) Clusters represent groups of miRNAs displaying similar alterations in expression over time after stimulation. Colors of lines within the clusters indicate the membership values of the expression profile to current cluster. Red and violet are high membership values and blue and green are low membership values. Members of each cluster are listed in Table S1. (B) Functional analysis of miRNA belonging to individual clusters. Functions associated with top networks according to Ingenuity Pathways are listed. (C) Functions belonging to “Neurological Disorder” and “Nervous System Development and Function” categories as defined by Ingenuity Pathways in individual miRNA clusters. Functions related to brain cancer and tumors are not included. Lists of functions with respective miRNAs are presented in Table S2.

http://dx.doi.org/10.1371/journal.pone.0076051.g003

Interestingly, we detected correlations in the expression levels of several miRNAs. For this analysis, we included miRNAs with expression levels that were significantly different between all sham and all stimulated animals (Figure 4). The highest positive correlation of expression was observed for miR-132-5p and miR-212-5p (0.98) miR-132-3p and miR-212-3p (0.97), miR-708-5p and miR-374-5p (0.94), and miR-374-5p and miR-31a-5p (0.94).

thumbnail
Figure 4. Correlation matrix of expression levels between miRNAs with expression that differs significantly between sham and stimulated animals

(Table 1.) The color and size of the circles in the matrix code for level of correlation; red represents positive correlation and blue represents negative correlation. Numerical values of correlations are presented in the lower left part of the matrix. Values that do not reach statistical significance are crossed.

http://dx.doi.org/10.1371/journal.pone.0076051.g004

To evaluate the potential functional impact of alterations in miRNAs expression levels, we decided to investigate if potential mRNA targets of the miRNA that change expression levels at 7 d and 30 d following SE also change their expression level. We concentrated on the expression of experimentally evaluated mRNAs defined by Ingenuity Pathways. We compared changes in miRNA expression evaluated with Exiqon microarrays and mRNA expression evaluated with Affymetrix microarrays in the dentate gyri of the same group of animals. Table 4 summarizes the potential target mRNAs that change expression in the opposite direction of the miRNA. Interestingly, several potential gene targets can be targeted by more than one miRNA. Moreover, some of these genes have been previously implicated in epileptogenesis or epilepsy (Table 4). Thus, we performed functional analysis of potential mRNA targets which revealed that target genes can be involved in several biological functions that have been previously associated with epilepsy, including regulation of transcription, response to wounding, apoptosis, cell proliferation, and immune response (Table 5).

IDmiRNA regulationTarget genep-valueLog Ratio
7 d
miR-212-3pupregulatedTLN2, talin 20.028-0.173
miR-21-5pupregulatedSESN1, sestrin 10.033-0.175
BTG2, BTG family, member 20.004-0.269
IL6R, interleukin 6 receptor0.012-0.276
SLC16A10, solute carrier family 16, member 10 (aromatic amino acid transporter)0.002-0.357
miR-124-3pdownregulatedARPC1B, actin related protein 2/3 complex, subunit 1B0.0010.704
TMBIM1, transmembrane BAX inhibitor motif containing 10.0000.641
GSN, gelsolin0.0320.566
NFATC1, nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 10.0030.534
PLP2, proteolipid protein 20.0080.508
CYP1B1, cytochrome P450, family 1, subfamily B, polypeptide 10.0090.485
CDK6, cyclin-dependent kinase 60.0000.437
RBMS1, RNA binding motif, single stranded interacting protein 10.0180.434
ELK3, ETS-domain protein (SRF accessory protein 2)0.0030.422
RHOG, ras homolog family member G0.0350.419
CTGF, connective tissue growth factor0.0110.369
BDNF, brain-derived neurotrophic factor0.0010.349
TJP2, tight junction protein 20.0030.345
TLN1, talin 10.0090.344
B4GALT1, UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 10.0020.321
PTTG1IP, pituitary tumor-transforming 1 interacting protein0.0270.307
MAGT1, magnesium transporter 10.0190.306
CAV1, caveolin 1, caveolae protein0.0280.280
RASSF5, Ras association (RalGDS/AF-6) domain family member 50.0060.273
FAM129B, family with sequence similarity 129, member B0.0360.271
RBM47, RNA binding motif protein 470.0120.256
LMNB1, lamin B10.0110.253
PLSCR3, phospholipid scramblase 30.0450.240
PTBP1, polypyrimidine tract binding protein 10.0220.236
CDK4, cyclin-dependent kinase 40.0090.208
ATP6V0E1, ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e10.0150.200
RELA, v-rel reticuloendotheliosis viral oncogene homolog A0.0380.172
DNM2, dynamin 20.0470.161
MAD2L2, MAD2 mitotic arrest deficient-like 20.0500.151
ELF4, E74-like factor 4 (ets domain transcription factor)0.0050.130
ALDH9A1, aldehyde dehydrogenase 9 family, member A10.0420.127
miR-301a-3pdownregulatedMAFB, v-maf musculoaponeurotic fibrosarcoma oncogene homolog B0.0010.576
CSF1, colony stimulating factor 10.0370.252
miR-30d-5pdownregulatedRBMS1, RNA binding motif, single stranded interacting protein 10.0180.434
CBFB, core-binding factor, beta subunit0.0440.403
CTGF, connective tissue growth factor0.0110.369
MET, met proto-oncogene (hepatocyte growth factor receptor)0.0030.283
TP53, tumor protein p530.0460.216
RUNX2, runt-related transcription factor 20.0140.207
SLC4A7, solute carrier family 4, sodium bicarbonate cotransporter, member 70.0430.189
miR-328a-3pdownregulatedCD44, CD44 molecule0.0010.713
miR-33-5pdownregulatedABCA1, ATP-binding cassette, sub-family A (ABC1), member 10.0030.634
miR-92b-3pdownregulatedENPP6, ectonucleotide pyrophosphatase/phosphodiesterase 60.0030.846
IKZF1, IKAROS family zinc finger 10.0000.521
CDKN1A, cyclin-dependent kinase inhibitor 1A0.0130.331
ITGA5, integrin, Ralpha 50.0330.170
30 d
miR-146a-5pupregulatedNFIX, nuclear factor I/X (CCAAT-binding transcription factor)0.033-0.090
PA2G4, Proliferation-Associated Protein 2G0.030-0.113
METTL7A, methyltransferase like 7A0.014-0.166
IL1RAP, interleukin 1 receptor accessory protein0.035-0.170
miR-21-5pupregulatedCDC25A, cell division cycle 25A0.011-0.137
SOCS5, suppressor of cytokine signaling 50.007-0.300
IL6R, interleukin 6 receptor0.018-0.318
SLC16A10, solute carrier family 16, member 10 (aromatic amino acid transporter)0.007-0.354
miR-23a-3pupregulatedSMAD5, SMAD family member 50.013-0.120
IL6R, interleukin 6 receptor0.018-0.318
miR-34a-5pupregulatedDLL1, delta-like 10.014-0.188
VEGFA, vascular endothelial growth factor A0.039-0.200
miR-29b-3pdownregulatedZFP36L1, ZFP36 ring finger protein-like 10.0280.287
SPARC, secreted protein, acidic, cysteine-rich (osteonectin)0.0120.260
COL1A2, collagen, type I, alpha 20.0320.186
miR-30e-5pdownregulatedCPNE8, copine VIII0.0280.372
ADPGK, ADP-dependent glucokinase0.0050.238
SLC7A11, solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 110.0410.230
TP53, tumor protein p530.0450.182
TMED10, transmembrane emp24-like trafficking protein 10 (yeast)0.0200.177
MPDU1, mannose-P-dolichol utilization defect 10.0440.144

Table 4. Predicted target genes for miRNAs that changed expression level at 7 d and 30 d after stimulation.

CSV
Download CSV
Biological functionGene name
7d
regulation of transcriptionBTG2, IKZF1, ELF4, MAFB, RELA, TP53, ELK3, RUNX2, CBFB, NFATC1, DNM2, PA2G4, VEGFA, SMAD5, NFIX
cell motionB4GALT1, ARPC1B, TLN1, BDNF, CD44, ITGA5, CTGF, MET, IL6R
response to woundingB4GALT1, CD44, ITGA5, CTGF, GSN, RELA, IL6R, ELK3
regulation of cell proliferationB4GALT1, CAV1, CSF1, RELA, TP53, CDK6, IL6R, CDK4, SESN1, BDNF, CDKN1A, BTG2, RUNX2, RHOG, PA2G4, VEGFA, TP53, CDC25A
cytoskeleton organizationARPC1B, TLN1, CAV1, TLN2, GSN
regulation of phosphorylationCDKN1A, CAV1, CSF1, MET, IL6R
membrane organizationCAV1, PLSCR3, TP53, ABCA1, DNM2
cation homeostasisCAV1, ATP6V0E1, TP53
intracellular signalingCAV1, RASSF5, CTGF, GSN, MET, TP53, ABCA1, RHOG, NFATC1, VEGFA, SMAD5, COL1A2, SOCS5
ion transportPLP2, CAV1, ATP6V0E1, SLC4A7, NFATC1
protein localizationTLN1, CAV1, TLN2, PTTG1IP, TP53, ABCA1
regulation of apoptosisRASSF5, GSN, TP53
immune responseIL1RAP, VEGFA, TP53, IL6R
30 d
intracellular signalingVEGFA, SMAD5, COL1A2, SOCS5, DLL1
cell proliferationPA2G4, VEGFA, TP53, CDC25A
regulation of transcriptionPA2G4, VEGFA, SMAD5, TP53, NFIX
Immune responseIL1RAP, VEGFA, TP53, IL6R
regulation of apoptosisVEGFA, TP53, IL6R

Table 5. Functional classification of potential target genes for miRNAs that changed expression levels at 7 d or 30 d after stimulation.

For gene name abbreviations see Table 4.
CSV
Download CSV

Discussion

Here, we show for the first time that prolonged changes in the expression of miRNAs in the rat dentate gyrus follow status epilepticus. We present lists of miRNAs that change expression levels as well as patterns of miRNA expression at different time points after status epilepticus. We also present the potential mRNA targets that could be regulated by miRNAs in the dentate gyrus and discuss the role of changes in miRNA expression in epilepsy.

miRNA has been recently implicated in a number of neurological diseases and psychiatric disorders, including brain tumors, ischemia, Alzheimer’s disease, schizophrenia, bipolar disorder and anxiety [15,42-45]. Alterations in the expression of some miRNAs have been shown in both epilepsy patients and experimental models (recently reviewed in [12]. In human temporal lobe epilepsy with hippocampal sclerosis, dysfunction of the miRNA processing machinery has been reported [21]. In the hippocampus of patients with epilepsy, McKierman et al. observed decreases in the expression of the Dicer protein, which was associated with reduced levels of mature miRNAs [21]. Kan et al. performed profiling of miRNA expression in the hippocampus and found specific miRNA expression signatures in control subjects and in epilepsy patients with and without hippocampal sclerosis [22]. A study by Abou-Zeid et al. concentrated on the role of miR-155. They showed an upregulation of miR-155 in the hippocampi of children with mesial temporal lobe epilepsy [20].

Few reports describing acute global changes in expression of miRNA following epileptogenic stimuli in experimental models have been recently published. Alterations in the expression of several miRNAs were observed in the rat hippocampus 24 hours following kainic acid-induced status epilepticus, ischemic stroke and intracerebral hemorrhage [46]. Alterations in miRNA expression were also found in hippocampal CA3 24 h following an intra-amygdala injection of kainic acid, in the hippocampus 24 h and 7 d following controlled cortical impact in rat, and in the hippocampus and hippocampal synaptoneurosomes at 4 h and 48 h following pilocarpine-induced status epilepticus [25,47,48].

Few data sets describe changes in the expression levels of miRNAs during chronic epilepsy in rats. The lithium-pilocarpine model of temporal lobe epilepsy was used in these studies. Hu et al. found an upregulation of 9 and a downregulation of 15 miRNAs in rat hippocampi 2 months after pilocarpine-induces status epilepticus [23] while Song et al. found downregulation of 5 and an upregulation of 18 miRNAs 60 d after pilocarpine application [24]. Moreover, changes in miRNA expression were studied in the hippocampus and hippocampal synaptoneurosomes at 4 h, 48 h and 3 wks following pilocarpine-induced status epilepticus [25].

In contrast to previous reports, which showed alterations in miRNA expression in the whole hippocampus, we were interested in miRNA expression profiles only in the dentate gyrus. By comparing the miRNA expression levels between all sham-operated and all stimulated animals regardless of the time point of tissue collection, we have identified a set of miRNAs that can have long-lasting effects on gene expression in the epileptic dentate gyrus (see Figure 1B, Table 1). On the other hand, the analysis of time-point specific alteration in miRNA expression between stimulated and time-matched sham-operated animals allowed us to distinguish miRNA whose actions may be more restricted in time (Figure 2, 3; Tables 2, 3). We can conclude that the patterns of miRNA expression are dynamic in time and unique for ensembles of miRNAs (Figure 3).

We have approached the issue of the role of alterations in the expression of miRNAs on the function of the epileptic brain by analyzing molecular networks that can be affected by the miRNAs detected in our study (Figure 3B, C). The Ingenuity Pathway analysis used for this analysis contains experimentally validated data on mRNAs targeted by miRNA combined with assembly of metabolic pathways also build on the basis of experimentally confirmed knowledge. Given that miRNAs have been extensively studied in cancer [49], it is not surprising that many functions assigned to miRNA clusters have been shown to be related to cancer. These include cancer, cell growth and proliferation, cell cycle, and hematological diseases. Some other functions, such as inflammatory disease and inflammatory response have been related to the pathophysiology of epilepsy because inflammation and immune response play an important role in this disease [8,50,51]. Interestingly, despite the obvious bias towards cancer related functions, we were able to detect functions specific for the brain. In particular, miRNAs from several of identified clusters are involved in Alzheimer’s disease, schizophrenia, and multiple sclerosis. Moreover, miRNA belonging to clusters 4 and 6, which increased in expression at early time points following stimulation, have a role in neuronal plasticity, because “LTP of CA1 neurons” and “quantity of mushroom spines” were assigned to these clusters. Both LTP and structural changes in spines have been previously implicated in epilepsy [52].

The other approach for understanding the functional impact of changes in miRNA expression in our experimental model was to distinguish the potential mRNA targets for miRNAs that changed expression levels in the dente gyrus. We took advantage of the transcriptome profiling data obtained from our rats and selected mRNAs that have been previously shown to be regulated by these miRNAs and changed expression levels in the dentate gyrus in the expected direction. We detected several target mRNAs that are potentially regulated by miRNA in the epileptic dentate gyrus. Protein products of these mRNAs are involved in several molecular events that occur in epileptic tissue, including the regulation of transcription, second messenger signaling, ion homeostasis, immune response, response to wounding, and regulation of cell death [8]. Interestingly, one of the potential target for several miRNAs is the receptor for interleukin 6 (IL6R). The role of cytokines, including the IL6 system has been extensively studied in epilepsy [53]. The upregulation of both IL6 and IL6R occurs following status epilepticus [54,55]. However there are no experimental data on the involvement of miRNA in the regulation of IL6R expression in the brain.

In general, the functions of the miRNAs that changed expression levels in the present experiment are related to inflammation, neuronal plasticity and neuronal development. However, the functions of even experimentally confirmed mRNA targets in the brain for the majority of miRNAs detected in our experiments, as well as for the presumed mRNA targets are not known. Altogether, understanding the impact of such orchestrated changes in miRNA expression on the function of brain tissue will require in-depth knowledge on the targets of each miRNA. At present, this knowledge is still fragmented, and for some miRNAs, it is non-existent.

Interestingly, we observed that there is an overlap between previously reported datasets derived from the epileptic hippocampus by others and our data set from the dentate gyrus. We found common expression of 9 miRNAs (miR-132, miR-137, miR-139, miR-29a, miR-324, miR-352, miR-282, miR-146a, and miR-23a) when our data were compared to a data set describing miRNA expression 60 d after pilocarpine-induced status epilepticus [24]. There are 6 common miRNAs (miR-138, miR-301a, miR-33, miR-34a, miR-146a, and miR-23a) between our data set and work of Hu et al. who studied miRNA expression profiles in a pilocarpine-induced model of epilepsy [23]. Additionally, four miRNAs (miR-138, miR-146b, miR-301a, and miR-92b) were common between our data and those of Kan et al. in human temporal lobe epilepsy [22]. Changes in the expression of miR-21 and miR-34a were found in our study and in a study by Risbud and Porter using the hippocampus from epileptic rats [25]. It can be argued that these changes in miRNAs expression detected in different brain areas, in human tissue, and in different experimental models of epilepsy are crucial for understanding the pathophysiology of the disease and may constitute interesting candidate targets for therapy. Interestingly, the role for some of these miRNAs frequently associated with epilepsy in different experimental setups has been already proposed.

For example, miR-146a is restricted to astrocytes and is overexpressed in activated astrocytes in human temporal lobe epilepsy and in experimental models [56-58]. This miRNA is crucial for regulation of astrocyte mediated inflammatory response by influencing IL-1β, IL-6 and COX-2 signaling [56].

Another miRNA, miR-132, is enriched in neurons and consistently upregulated following epileptogenic stimuli [57]. Its expression can be induced by neuronal activity and is regulated by CREB, transcription factor, which is also implicated in temporal lobe epilepsy [59]. miR-132 strongly influences neuronal morphology, increasing dendritic outgrowth and arborization [60]. It is also necessary for neuronal spine formation, and the overexpression of miR-132 results in increased spine density [61,62]. Furthermore, the overexpression or knock-down of miR-132 in the brain modulates learning and memory in several experimental paradigms [62-65]. In addition to its role in neuronal plasticity, miR-132 can participate also in neurodegeneration. In particular, following an intra-amygldala injection of kainic acid, the depletion of miR-132 reduces seizure-induced neurodegeneration [48].

Another miRNA that may be involved in neuroprotection is miR-34a. Its expression is acutely upregulated following status epilepticus and is also observed in epileptic animals [23,25]. The use of antagomirs against miR-34a decreased apoptotic markers in the hippocampus following pilocarpine-induced status epilepticus but was not effective in the intra-amygdala kainic acid injection model [23,66].

Although the effect of changes in expression of whole sets of miRNAs on function of brain tissue cannot currently be predicted there is a role for several individual miRNAs in epilepsy.

We conclude that complex changes in the expression of miRNAs in epileptic dentate gyrus and changes in expression of their potential mRNA targets suggest an important role for miRNA in molecular mechanisms of epilepsy, especially those related to inflammation and neuronal plasticity.

Supporting Information

Table S1.

Members of gene clusters presented on Figure 3, representing groups of miRNAs displaying similar alterations in expression over time after stimulation.

doi:10.1371/journal.pone.0076051.s001

(XLS)

Table S2.

Lists of functions assigned to individual miRNAs present in clusters on Figure 3.

doi:10.1371/journal.pone.0076051.s002

(XLS)

Acknowledgments

We would like to thank Ewa Nosecka and Joanna Bednarczyk for expert technical help.

Author Contributions

Conceived and designed the experiments: KL. Performed the experiments: AB KD. Analyzed the data: AB KD KL. Wrote the manuscript: AB KD KL.

References

  1. 1. Banerjee PN, Hauser WA (2008) Incidence and prevalence. In: J. EngelTA Pedley. Epilepsy. A comprehensive textbook. 2nd ed. Baltimore: Wolters Kluwer (Lippincott Williams & Wilkins). pp. 45-56.
  2. 2. Sisodiya S (2007) Etiology and management of refractory epilepsies. Nat Clin Pract Neurol 3: 320-330. doi:10.1038/ncpendmet0432. PubMed: 17549058.
  3. 3. Mathern GW, Babb TL, Leite JP, Pretorius K, Yeoman KM et al. (1996) The pathogenic and progressive features of chronic human hippocampal epilepsy. Epilepsy Res 26: 151-161. doi:10.1016/S0920-1211(96)00052-6. PubMed: 8985697.
  4. 4. Pitkanen A, Lukasiuk K (2009) Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 14 Suppl 1: 16-25. doi:10.1016/j.yebeh.2008.09.023. PubMed: 18835369.
  5. 5. Pitkänen A, Lukasiuk K (2011) Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 10: 173-186. doi:10.1016/S1474-4422(10)70310-0. PubMed: 21256455.
  6. 6. Gorter JA, Van Vliet EA, Rauwerda H, Breit T, Stad R et al. (2007) Dynamic changes of proteases and protease inhibitors revealed by microarray analysis in CA3 and entorhinal cortex during epileptogenesis in the rat. Epilepsia 48 Suppl 5: 53-64. doi:10.1111/j.1528-1167.2007.01290.x. PubMed: 17910582.
  7. 7. Gorter JA, van Vliet EA, Aronica E, Breit T, Rauwerda H et al. (2006) Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J Neurosci 26: 11083-11110. doi:10.1523/JNEUROSCI.2766-06.2006. PubMed: 17065450.
  8. 8. Lukasiuk K, Dabrowski M, Adach A, Pitkänen A (2006) Epileptogenesis-related genes revisited. Prog Brain Res 158: 223-241. doi:10.1016/S0079-6123(06)58011-2. PubMed: 17027699.
  9. 9. Cacheaux LP, Ivens S, David Y, Lakhter AJ, Bar-Klein G et al. (2009) Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci 29: 8927-8935. doi:10.1523/JNEUROSCI.0430-09.2009. PubMed: 19605630.
  10. 10. Beaumont TL, Yao B, Shah A, Kapatos G, Loeb JA (2012) Layer-specific CREB target gene induction in human neocortical epilepsy. J Neurosci 32: 14389-14401. doi:10.1523/JNEUROSCI.3408-12.2012. PubMed: 23055509.
  11. 11. Kobow K, Blümcke I (2012) The emerging role of DNA methylation in epileptogenesis. Epilepsia 53 Suppl 9: 11-20. doi:10.1111/epi.12031. PubMed: 23216575.
  12. 12. Jimenez-Mateos EM, Henshall DC (2013) Epilepsy and microRNA. Neuroscience 238: 218-229. doi:10.1016/j.neuroscience.2013.02.027. PubMed: 23485811.
  13. 13. Ebert MS, Sharp PA (2012) Roles for microRNAs in conferring robustness to biological processes. Cell 149: 515-524. doi:10.1016/j.cell.2012.04.005. PubMed: 22541426.
  14. 14. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E et al. (2004) Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol 5: R13. doi:10.1186/gb-2004-5-3-r13. PubMed: 15003116.
  15. 15. Malan-Muller S, Hemmings SM, Seedat S (2013) Big effects of small RNAs: a review of microRNAs in anxiety. Mol Neurobiol 47: 726-739. doi:10.1007/s12035-012-8374-6. PubMed: 23150170.
  16. 16. Wang W, Kwon EJ, Tsai LH (2012) MicroRNAs in learning, memory, and neurological diseases. Learn Mem 19: 359-368. doi:10.1101/lm.026492.112. PubMed: 22904366.
  17. 17. Saugstad JA (2010) MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection, and neurodegeneration. J Cereb Blood Flow Metab 30: 1564-1576. doi:10.1038/jcbfm.2010.101. PubMed: 20606686.
  18. 18. Coolen M, Bally-Cuif L (2009) MicroRNAs in brain development and physiology. Curr Opin Neurobiol 19: 461-470. doi:10.1016/j.conb.2009.09.006. PubMed: 19846291.
  19. 19. Schouten M, Aschrafi A, Bielefeld P, Doxakis E, Fitzsimons CP (2013) microRNAs and the regulation of neuronal plasticity under stress conditions. Neuroscience 241: 188-205. doi:10.1016/j.neuroscience.2013.02.065. PubMed: 23500144.
  20. 20. Abou-Zeid A, Saad M, Soliman E (2013) MicroRNA 146a expression in rheumatoid arthritis: association with tumor necrosis factor-alpha and disease activity. Genet Tests Mol Biomarkers 15: 807-812. PubMed: 21810022.
  21. 21. McKiernan RC, Jimenez-Mateos EM, Bray I, Engel T, Brennan GP et al. (2012) Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLOS ONE 7: e35921. doi:10.1371/journal.pone.0035921. PubMed: 22615744.
  22. 22. Kan AA, van Erp S, Derijck AA, de Wit M, Hessel EV et al. (2012) Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. Cell Mol Life Sci 69: 3127-3145. doi:10.1007/s00018-012-0992-7. PubMed: 22535415.
  23. 23. Hu K, Xie YY, Zhang C, Ouyang DS, Long HY et al. (2012) MicroRNA expression profile of the hippocampus in a rat model of temporal lobe epilepsy and miR-34a-targeted neuroprotection against hippocampal neurone cell apoptosis post-status epilepticus. BMC Neurosci 13: 115. doi:10.1186/1471-2202-13-115. PubMed: 22998082.
  24. 24. Song YJ, Tian XB, Zhang S, Zhang YX, Li X et al. (2011) Temporal lobe epilepsy induces differential expression of hippocampal miRNAs including let-7e and miR-23a/b. Brain Res 1387: 134-140. doi:10.1016/j.brainres.2011.02.073. PubMed: 21376023.
  25. 25. Risbud RM, Porter BE (2013) Changes in microRNA expression in the whole hippocampus and hippocampal synaptoneurosome fraction following pilocarpine induced status epilepticus. PLOS ONE 8: e53464. doi:10.1371/journal.pone.0053464. PubMed: 23308228.
  26. 26. Dudek FE, Sutula TP (2007) Epileptogenesis in the dentate gyrus: a critical perspective. Prog Brain Res 163: 755-773. doi:10.1016/S0079-6123(07)63041-6. PubMed: 17765749.
  27. 27. Houser CR, Zhang N, Peng Z, Huang CS, Cetina Y (2012) Neuroanatomical clues to altered neuronal activity in epilepsy: from ultrastructure to signaling pathways of dentate granule cells. Epilepsia 53 Suppl 1: 67-77. doi:10.1111/j.1528-1167.2011.03329.x. PubMed: 22612811.
  28. 28. Parent JM, Murphy GG (2008) Mechanisms and functional significance of aberrant seizure-induced hippocampal neurogenesis. Epilepsia 49 Suppl 5: 19-25. doi:10.1111/j.1528-1167.2008.01634.x. PubMed: 18522597.
  29. 29. Nissinen J, Halonen T, Koivisto E, Pitkänen A (2000) A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res 38: 177-205. doi:10.1016/S0920-1211(99)00088-1. PubMed: 10642046.
  30. 30. Guzik-Kornacka A, Sliwa A, Plucinska G, Lukasiuk K (2011) Status epilepticus evokes prolonged increase in the expression of CCL3 and CCL4 mRNA and protein in the rat brain. Acta Neurobiol Exp Wars 71: 193-207. PubMed: 21731074.
  31. 31. Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. sixth ed. Amsterdam: Elsevier.
  32. 32. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5: R80. doi:10.1186/gb-2004-5-10-r80. PubMed: 15461798.
  33. 33. R_Core_Team (2012) A language and environment for statistical computing. R Foundation for Statistical Computing. In. Vienna: Available: http://www.R-project.org/.
  34. 34. Smyth G (2005) Limma: linear models for microarray data. In: RVC GentlemanS. DudoitR. IrizarryW. Huber. Bioinformatics and Computational Biology Solutions using R and Bioconductor. New York: Springer Verlag. pp. 397-420.
  35. 35. Sakar D (2008) Lattice: Multivariate Data Visualization with R. New York: Springer Verlag.
  36. 36. Warnes GR (2012) gplots: Various R programming tools for plotting data. R package version 2.11.0.
  37. 37. Wei T (2012) corrplot: Visualization of a correlation matrix. R package version 0.70.
  38. 38. Futschik M (2012) Mfuzz: Soft clustering of time series gene expression data. R package version 2.16.0.
  39. 39. Carvalho BS, Irizarry RA (2010) A framework for oligonucleotide microarray preprocessing. Bioinformatics 26: 2363-2367. doi:10.1093/bioinformatics/btq431. PubMed: 20688976.
  40. 40. Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57. PubMed: 19131956.
  41. 41. Huang da W, Sherman BT, Lempicki RA (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13. doi:10.1093/nar/gkp505. PubMed: 19033363.
  42. 42. Banigan MG, Kao PF, Kozubek JA, Winslow AR, Medina J et al. (2013) Differential expression of exosomal microRNAs in prefrontal cortices of schizophrenia and bipolar disorder patients. PLOS ONE 8: e48814. doi:10.1371/journal.pone.0048814. PubMed: 23382797.
  43. 43. Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M et al. (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47: 131-144. doi:10.1007/s12035-012-8349-7. PubMed: 23054677.
  44. 44. Wang Y, Wang Y, Yang GY (2013) MicroRNAs in Cerebral Ischemia. Stroke Res Treat 2013: 276540.
  45. 45. Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM et al. (2013) De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer’s disease. Hum Mol Genet 22: 3077-3092. doi:10.1093/hmg/ddt164. PubMed: 23585551.
  46. 46. Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS et al. (2010) Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab 30: 92-101. doi:10.1038/jcbfm.2009.186. PubMed: 19724284.
  47. 47. Hu Z, Yu D, Almeida-Suhett C, Tu K, Marini AM et al. (2012) Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury. PLOS ONE 7: e39357. doi:10.1371/journal.pone.0039357. PubMed: 22761770.
  48. 48. Jimenez-Mateos EM, Bray I, Sanz-Rodriguez A, Engel T, McKiernan RC et al. (2011) miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. Am J Pathol 179: 2519-2532. doi:10.1016/j.ajpath.2011.07.036. PubMed: 21945804.
  49. 49. Ciafrè SA, Galardi S (2013) microRNAs and RNA-binding proteins: A complex network of interactions and reciprocal regulations in cancer. RNA Biol 10: 935-943. doi:10.4161/rna.24641. PubMed: 23696003.
  50. 50. Vezzani A, Aronica E, Mazarati A (2013) Pittman QJ. Epilepsy and brain inflammation. Exp Neurol 244: 11-21. doi:10.1016/j.expneurol.2011.09.033. PubMed: 21985866.
  51. 51. Vezzani A, Friedman A, Dingledine RJ (2013) The role of inflammation in epileptogenesis. Neuropharmacology 69: 16-24. doi:10.1016/j.neuropharm.2012.04.004. PubMed: 22521336.
  52. 52. Leite JP, Neder L, Arisi GM, Carlotti CG Jr., Assirati JA et al. (2005) Plasticity, synaptic strength, and epilepsy: what can we learn from ultrastructural data? Epilepsia 46 Suppl 5: 134-141. doi:10.1111/j.1528-1167.2005.01021.x. PubMed: 15987268.
  53. 53. Vezzani A, Balosso S, Ravizza T (2008) The role of cytokines in the pathophysiology of epilepsy. Brain Behav Immun 22: 797-803. doi:10.1016/j.bbi.2008.03.009. PubMed: 18495419.
  54. 54. Lehtimäki KA, Peltola J, Koskikallio E, Keränen T, Honkaniemi J (2003) Expression of cytokines and cytokine receptors in the rat brain after kainic acid-induced seizures. Brain Res. Mol Brain Res 110: 253-260. doi:10.1016/S0169-328X(02)00654-X. PubMed: 12591161.
  55. 55. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M et al. (2000) Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 12: 2623-2633. doi:10.1046/j.1460-9568.2000.00140.x. PubMed: 10947836.
  56. 56. Iyer A, Zurolo E, Prabowo A, Fluiter K, Spliet WG et al. (2012) MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLOS ONE 7: e44789. doi:10.1371/journal.pone.0044789. PubMed: 23028621.
  57. 57. Jovičić A, Roshan R, Moisoi N, Pradervand S, Moser R et al. (2013) Comprehensive Expression Analyses of Neural Cell-Type-Specific miRNAs Identify New Determinants of the Specification and Maintenance of Neuronal Phenotypes. J Neurosci 33: 5127-5137. doi:10.1523/JNEUROSCI.0600-12.2013. PubMed: 23516279.
  58. 58. Aronica E, Fluiter K, Iyer A, Zurolo E, Vreijling J et al. (2010) Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur J Neurosci 31: 1100-1107. doi:10.1111/j.1460-9568.2010.07122.x. PubMed: 20214679.
  59. 59. Nudelman AS, DiRocco DP, Lambert TJ, Garelick MG, Le J et al. (2010) Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo. Hippocampus 20: 492-498.
  60. 60. Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH et al. (2010) microRNA-132 regulates dendritic growth and arborization of newborn neurons in the adult hippocampus. Proc Natl Acad Sci U S A 107: 20382-20387. doi:10.1073/pnas.1015691107. PubMed: 21059906.
  61. 61. Impey S, Davare M, Lesiak A, Fortin D, Ando H et al. (2010) An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling. Mol Cell Neurosci 43: 146-156. doi:10.1016/j.mcn.2009.10.005. PubMed: 19850129.
  62. 62. Hansen KF, Sakamoto K, Wayman GA, Impey S, Obrietan K (2010) Transgenic miR132 alters neuronal spine density and impairs novel object recognition memory. PLOS ONE 5: e15497. doi:10.1371/journal.pone.0015497. PubMed: 21124738.
  63. 63. Hansen KF, Karelina K, Sakamoto K, Wayman GA, Impey S et al. (2012) miRNA-132: a dynamic regulator of cognitive capacity. Brain Struct Funct 218: 817-831. PubMed: 22706759.
  64. 64. Scott HL, Tamagnini F, Narduzzo KE, Howarth JL, Lee YB et al. (2012) MicroRNA-132 regulates recognition memory and synaptic plasticity in the perirhinal cortex. Eur J Neurosci 36: 2941-2948. doi:10.1111/j.1460-9568.2012.08220.x. PubMed: 22845676.
  65. 65. Wang RY, Phang RZ, Hsu PH, Wang WH, Huang HT et al. (2013) In vivo knockdown of hippocampal miR-132 expression impairs memory acquisition of trace fear conditioning. Hippocampus 23: 625-633. doi:10.1002/hipo.22123. PubMed: 23520022.
  66. 66. Sano T, Reynolds JP, Jimenez-Mateos EM, Matsushima S, Taki W et al. (2012) MicroRNA-34a upregulation during seizure-induced neuronal death. Cell Death. Drosophila Inf Serv 3: e287.